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Background: Thymidine analogue resistance mutations (TAMs) selected under treatment with nucleoside
analogues generate two distinct genotypic profiles in the HIV-1 reverse transcriptase (RT): (i) TAM1: M41L, L210W
and T215Y, and (ii) TAM2: D67N, K70R and K219E/Q, and sometimes T215F. Secondary mutations, including thumb
subdomain polymorphisms (e.g. R284K) have been identified in association with TAMs. We have identified
mutational clusters associated with virological failure during salvage therapy with tenofovir/emtricitabine-based
regimens. In this context, we have studied the role of R284K as a secondary mutation associated with mutations of
the TAM1 complex.
Results: The cross-sectional study carried out with >200 HIV-1 genotypes showed that virological failure to
tenofovir/emtricitabine was strongly associated with the presence of M184V (P < 10-10) and TAMs (P < 10-3), while
K65R was relatively uncommon in previously-treated patients failing antiretroviral therapy. Clusters of mutations
were identified, and among them, the TAM1 complex showed the highest correlation coefficients. Covariation of
TAM1 mutations and V118I, V179I, M184V and R284K was observed. Virological studies showed that the
combination of R284K with TAM1 mutations confers a fitness advantage in the presence of zidovudine or tenofovir.
Studies with recombinant HIV-1 RTs showed that when associated with TAM1 mutations, R284K had a minimal
impact on zidovudine or tenofovir inhibition, and in their ability to excise the inhibitors from blocked DNA primers.
However, the mutant RT M41L/L210W/T215Y/R284K showed an increased catalytic rate for nucleotide incorporation
and a higher RNase H activity in comparison with WT and mutant M41L/L210W/T215Y RTs. These effects were
consistent with its enhanced chain-terminated primer rescue on DNA/DNA template-primers, but not on RNA/DNA
complexes, and can explain the higher fitness of HIV-1 having TAM1/R284K mutations.
Conclusions: Our study shows the association of R284K and TAM1 mutations in individuals failing therapy with
tenofovir/emtricitabine, and unveils a novel mechanism by which secondary mutations are selected in the context
of drug-resistance mutations.* Correspondence: lmenendez@cbm.uam.es
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Highly active antiretroviral therapy (HAART) regimens
containing two nucleoside reverse transcriptase inhibitors
(NRTIs) and either a non-nucleoside RT inhibitor (NNRTI)
or a ritonavir-boosted protease inhibitor have become
standard practice in the treatment of human immunodefi-
ciency virus type 1 (HIV-1) infection. Despite the efficacy of
current HAART regimens, the emergence of drug resis-
tance is still a major threat to therapy success [1]. Reverse
transcriptase (RT) inhibitors have been prescribed since the
approval of zidovudine (AZT, 3´-azido-3´-deoxythymidine)
in 1987, and NRTIs have been extensively used for the last
25 years [2,3]. Therefore, the burden of drug resistance
among previously treated patients poses additional risk of
therapy failure in those individuals.
NRTIs mimic natural nucleosides that are converted
to triphosphate derivatives inside the cell. In this form,
NRTIs act as competitive inhibitors of HIV-1 RT. NRTIs
lack a 3´-OH group in their ribose ring, and their in-
corporation into the newly synthesized DNA results in
chain termination [2,4]. Mutations conferring resistance
to NRTIs can act by improving discrimination against
nucleotide analogues [5-7] or by enhancing the excision
of the inhibitor from the terminated DNA chain
through phosphorolysis mediated by ATP or pyrophos-
phate (PPi) [8,9]. Mutations such as M184V or M184I
conferring resistance to lamivudine or emtricitabine are
known to affect nucleotide discrimination [5]. However,
combinations of M41L, D67N, K70R, L210W, T215F/Y
and K219E/Q increase ATP-mediated excision of chain-
terminating NRTIs (reviewed in ref. [4]). DNA primers
terminated with thymidine analogues (AZT or 2´,3´-dide-
hydro-2´,3´-dideoxythymidine (d4T, stavudine)) or tenofo-
vir are good substrates of the excision reaction. In contrast,
cytidine analogues (e.g. lamivudine or emtricitabine) are
removed very inefficiently [9-15]; (reviewed in ref. [1]).
Sequence analysis of HIV-1 isolates from patients re-
ceiving long-term therapy with AZT and/or d4T
revealed that thymidine analogue resistance mutations
(TAMs) acting through the excision mechanism asso-
ciated in two different clusters: TAM1 (M41L, L210W
and T215Y) and TAM2 (D67N, K70R, K219E/Q, and
sometimes T215F) [16-18]. In addition, deletions affect-
ing Asp67 are usually linked to TAM2 mutations [19],
while dipeptide insertions at positions 69–70 associate
with both TAM1 and TAM2 clusters [20]. TAM1 is
more prevalent and confers a higher degree of resistance
to thymidine analogues. The factors determining the se-
lection of TAM1 or TAM2 pathways are not known, al-
though the sequence background of the viral population
could have a significant influence.
Standard genotypic analysis is usually restricted to
HIV-1 RT residues 1 to 240, including the fingers and
palm subdomains of the viral polymerase. Large cross-sectional studies have shown an association between
TAMs and mutations at codons 35, 39, 43, 122, 203,
207, 208, 214, 218, 223 and 228 of the RT-coding region
in HIV-1 isolates from patients failing NRTI-based ther-
apy [21-23]. Studies with recombinant HIV-1 have
shown that the amino acid substitutions K43E, Q207D
and F214L influence the viral replication capacity in the
presence of TAMs [24-26]. More recently, several studies
have demonstrated that RT residues in the thumb-
connection subdomains (residues 241 to 424) and in the
RNase H domain (425 to 560) could modulate NRTI sus-
ceptibility [27-30]. Examples are E312Q, G335C/D, N348I,
A360I/V, V365I and A376S in the HIV-1 RT connection
subdomain, and Q509L, H539N and D549N in the RNase
H domain [29-31]. In the presence of TAMs, those amino
acid substitutions seem to promote AZT resistance by
altering the balance between ATP-dependent excision of
AZT-terminated primers and RNase H degradation, on
RNA/DNA template-primers [32-34]. However, there are
also mutations that enhance the effect of TAMs through
an RNase H-independent mechanism, either by increasing
the RT processivity (e.g. N348I or A360V) [34] or its affin-
ity for short RNA/DNA duplexes (e.g. Q509L) [32].
Previously, we showed that RT thumb subdomain
polymorphisms associated with nucleoside analogue
therapy failure (i.e. P272A, R277K and T286A) altered
the HIV-1 replication capacity in the presence and in
the absence of TAMs, such as M41L and T215Y [35,36].
RTs with the combination Pro272/Arg277/Thr286 showed
increased efficiency in rescuing DNA primers terminated
with thymidine analogues and annealed to RNA tem-
plates [36]. Those effects were related to the higher af-
finity for RNA/DNA complexes shown by RTs having
Pro, Arg, and Thr at positions 272, 277 and 286, respect-
ively, but were independent of their intrinsic RNase H
activities. Genotypic analyses carried out with large data-
bases including treated and naïve HIV-infected patients
from the U.S. and Europe showed the significantly
higher prevalence of R284K in the treated population
[37] and its association with the accumulation of TAMs
[22]. According to the Stanford HIV Drug Resistance Data-
base (http://hivdb.stanford.edu/; accessed on July 6th, 2012),
the frequency of R284K in HIV-1 group M – subtype B
RTs found in naïve patients is estimated at 1.9%, while this
figure goes up to 4.1% when the analysis is carried out with
sequences from NRTI-treated individuals.
In this work, we show that R284K is associated with
TAM1 mutations in patients failing treatment with teno-
fovir/emtricitabine-based therapies. The significance of
this association is supported by the results of viral replica-
tion assays carried out in the presence of AZT and tenofo-
vir. Enzymological studies provide evidence on the role of
R284K as a polymorphism that enhances primer rescue by
promoting DNA synthesis after NRTI excision.
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Mutations associated with tenofovir/emtricitabine-based
therapy failure
After approval of tenofovir disoproxil fumarate and emtrici-
tabine, this combination has been frequently used in rescue
therapies with patients failing HAART regimens. However,
the presence of drug-resistance mutations at baseline, par-
ticularly TAMs, limits the efficacy of such a treatment. We
have performed a retrospective analysis of RT sequences
obtained from patients treated in Spanish hospitals that
failed combination therapies including tenofovir and emtri-
citabine. A total of 222 HIV-1 genotypes were examined,
118 of them were from naïve individuals and 104 from
previously-treated patients that did not respond to therap-
ies including tenofovir and emtricitabine as the only nu-
cleoside analogues in the salvage regimen. In most cases,
salvage therapies involved co-administration of NRTIs to-
gether with protease inhibitors (64.4% of the patients),
NNRTIs (usually efavirenz) (26.9% of the patients) or with
both groups of drugs. All therapies included at least three
different drugs.
The comparison of RT mutation frequencies in treated
and naïve populations revealed that M184V was strongly
associated with virological failure (viral load above 1000
RNA copies/ml) (P < 2 x 10-14) (Table 1), although sev-
eral TAMs (e.g. M41L, D67N, L210W, T215F, etc.. . .)
and NNRTI resistance mutations (e.g. K103N, Y181C
and G190A) were also associated with therapy failure, all
with P values below 5 x 10-4. The frequency of accessory
mutations such as T39A, H208Y and L228H was also
significantly higher in the treated population compared
with the naïve group. In the RT thumb subdomain, sig-
nificant differences were found for R284K and V292I
whose frequency was 3.8 and 1.9 times higher in the
population failing HAART (P < 0.05).
Covariation and mutational clusters
Pair-wise binary (phi) correlation coefficients were calcu-
lated to identify patterns of drug resistance mutations in
patients failing treatment with tenofovir and emtricita-
bine. The strongest correlations between mutations
associated with therapy failure were found with TAMs
M41L, L210W and T215Y, which form the TAM1 clus-
ter (Additional file 1: Table S1). Higher levels of signifi-
cance were also detected for other pairs of TAMs, such
as K70R and K219Q, D67N and K70R, and T215F and
K219Q. Interestingly, T69N appeared to be strongly cor-
related with K219Q (phi = 0.76, P = < 10-14) but also
with K70R (phi = 0.50, P < 10-6). M41L and T215Y were
also strongly correlated with V118I (P < 10-6), and with
accessory mutations Q174R and L228H.
Those data suggested the existence of clusters of
mutations at baseline that compromised response to
therapy. To identify those clusters we performed aprincipal axis factoring analysis. This computational pro-
cedure allows for the identification of underlying rela-
tionships between correlated mutations. The amino acid
substitutions that were significant for pair-wise correla-
tions were used in the factor analysis. The measure of
sample adequacy (Kaiser-Meyer-Olkin criterion) was
0.72, and a Bartlett test of sphericity became significant
(χ2 1794, df = 300, p < 0.0001). Five relevant factors were
obtained after using a scree plot, and taking eigenvalues
greater than 1.50. These five factors explained 59.0% of
the total variance of inter-correlations, while the first
three explained 45.0% of the total variance (Additional
file 1: Table S2). The graphical representation of these
three major factors revealed three clusters of mutations:
(1) A98G, Q174R, I178L and L228H (factor 1); (2)
M41L, L210W and T215Y (i.e. TAM1 pathway) (factor
2); and (3) D67N, K70R, T215F and K219Q (i.e. TAM2
pathway) (factor 3) (Figure 1).
Clusters (2) and (3) include all major TAMs. No clus-
tering was observed for the characteristic tenofovir re-
sistance mutation K65R. Our analysis showed that
mutations A62V, Y181C, G190A, H208Y and T215F
could cluster with the first group, although the associ-
ation was weaker than for A98G, Q174R, I178L and
L228H. Amino acid substitutions D67N, L74I, K223E
and L228H associate with the TAM2 cluster, while
V118I, V179I, M184V and R284K are linked to cluster
(2) formed by mutations of the TAM1 pathway. Among
those four mutations, R284K was the only one that
showed a positive value (0.356) associated with factor 2,
while having negative values for all other factors
included in the analysis (Additional file 1: Table S2).
R284K was often identified in sequences containing one
or more mutations of the TAM1 cluster, but lacking
M184V. Furthermore, the strongest correlation involving
R284K was found with T215Y (phi = 0.42; P < 2 x 10-5)
(Additional file 1: Table S1). The association of R284K
with TAM1 mutations was consistent with previous
reports demonstrating the higher prevalence of R284K
in the NRTI-treated population [22,37,38].
NRTI susceptibility and replication capacity of HIV-1 with
RT mutations M41L, L210W, T215Y and R284K
The association between R284K and mutations of the
TAM1 cluster was tested in the presence of drugs using
recombinant HIV-1. As expected, phenotypic drug sus-
ceptibility assays showed that the combination M41L/
L210W/T215Y had a significant impact on AZT resist-
ance, but a minor effect on HIV-1 susceptibility to d4T,
tenofovir and emtricitabine (Table 2). Addition of R284K
to the TAM1 cluster produced a subtle increase in the
IC50 for AZT, which was 5.8 times higher than the IC50
obtained with the WT virus. All tested viruses were found
to be susceptible to d4T and tenofovir due to the relatively
Table 1 Nucleoside RT inhibitor-related mutation frequencies in treatment-experienced and naïve patients
Naïve Tenofovir/Emtricitabine therapy failure
Mutation Mutation frequency(%) Mutation frequency(%) P
V35I 11.0 23.1 1.82 x 10-2
T39A 5.1 17.3 3.75 x 10-3
M41L 2.5 23.1 3.07 x 10-6
A62V - 6.7 4.87 x 10-3
K65R - 3.8 ns
D67N - 21.2 1.42 x 10-7
T69N - 7.7 2.13 x 10-3
K70R - 14.4 2.02 x 10-5
L74I - 5.8 1.08 x 10-2
A98G 1.7 7.7 3.65 x 10-2
K103N 4.2 21.2 1.25 x 10-4
V108I - 13.5 3.99 x 10-5
V118I 2.5 13.5 2.46 x 10-3
S162A 8.5 1.9 3.59 x 10-2
Q174R - 5.8 1.09 x 10-2
V179I 2.5 10.6 1.57 x 10-2
Y181C - 17.3 2.47 x 10-6
M184V 0.8 42.3 1.76 x 10-14
G190A - 15.4 1.00 x 10-5
H208Y - 9.6 5.99 x 10-4
L210W 0.8 18.3 6.23 x 10-6
L214F 79.7 91.3 1.65 x 10-2
T215F - 10.6 3.05 x 10-4
T215Y - 19.2 6.00 x 10-7
K219E - 7.7 2.14 x 10-3
K219Q 0.8 9.6 2.89 x 10-3
K223E - 4.8 2.44 x 10-2
L228H - 9.6 6.02 x 10-4
L228R - 7.7 2.16 x 10-3
R284K 2.5 9.6 2.87 x 10-2
V292I 11.0 21.2 4.49 x 10-2
E297K 19.5 35.6 7.82 x 10-3
G333E 6.8 15.4 4.60 x 10-2
Reported P-values indicate statistically significant differences, corrected for the multiple-hypothesis testing by the Benjamini-Hochberg method, with a false
discovery rate of 0.05 with respect to the results from isolates from drug-naïve patients (N = 118). For the chi-square contingency tests, the therapy failure group
(N = 104) included samples from patients who were receiving the inhibitor at the time of genotypic testing and showed a viral load above 1000 RNA copies per
ml. ns, not significant.
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http://www.retrovirology.com/content/9/1/68high dNTP concentrations present in MT-4 cells used in
these assays. Under these conditions, phosphorolysis de-
pending on ATP or PPi might be inhibited due to the for-
mation of “dead-end complexes” [9,39], and therefore the
contribution of M41L, L210W and T215Y to tenofovir and
d4T resistance was barely detectable.
In the presence of tenofovir, growth competition assays
carried out in MT-4 cells failed to show significantdifferences between HIV-1 clones containing RT variants
M41L/L210W/T215Y and M41L/L210W/T215Y/R284K
(data not shown). Therefore, viral fitness was assayed in
peripheral blood mononuclear cells (PBMCs), in the pre-
sence of AZTand tenofovir. The lower nucleotide concen-
trations found in primary human PBMCs facilitate the
detection of minor differences in virus replication efficien-
cies [40]. Mutants M41L/L210W/T215Y and M41L/
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Figure 1 Principal axis factoring analysis of correlations
between mutations associated with tenofovir/emtricitabine
therapy failure. A factor scores plot (in rotated factor space) is
shown. Amino acid changes with high coefficients of covariation are
close together, while large distances separate those substitutions
that show low or negative coefficients of association. Major
mutations of the TAM1 and TAM2 complexes are indicated in red
and blue, respectively.
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Figure 2 Replication kinetics of WT and mutant RTs in the
absence and presence of AZT and tenofovir disoproxil
fumarate (Tenofovir-DF). In each case, histograms show the
relative replication capacity (%), compared to the WT virus in the
absence of drug, based on the slopes of p24 antigen production of
each recombinant virus after infection of stimulated PBMCs. The
significance of the difference between slopes was calculated using
the GraphPrism v. 4 software and significant p values are
represented above the bars. Statistical analyses were performed by
using a Student t test.
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drugs showed decreased replication capacity compared to
the WT virus (Figure 2). Under these conditions, R284K
had a detrimental effect on viral fitness. However, in the
presence of AZT or tenofovir, this amino acid change pro-
duced a significant increase in the replication capacity of
HIV-1 bearing mutations M41L, L210W and T215Y.
Thus, R284K had a compensatory effect on the loss of fit-
ness caused by the TAM1 cluster of mutations, in the
presence of NRTIs.
Contribution of R284K to ATP-mediated rescue of primers
terminated with NRTIs
The ability of RTs to unblock AZTMP-, d4TMP- and
tenofovir-terminated primers was first assessed with
DNA/DNA template-primers (Figure 3). In the presence
of 3.2 mM ATP, we observed that with all NRTIs, the
addition of R284K to a mutational background constitutedTable 2 Susceptibility of HIV-1 constructs to nucleoside RT in
RTs AZT d4T
WT 2.3 ± 1.5 276.0
R284K 1.7 ± 1.1 (0.7) 130.0
M41L/L210W/T215Y 11.7 ± 1.1 (5.1) 217.0
M41L/L210W/T215Y/R284K 13.3 ± 1.5 (5.8) 287.3
The IC50 values represent averages ± standard deviations of at least three tests, with
type HXB2 virus control carrying the RT sequence of BH10 is shown between paren
a Experiments were carried out with the water soluble diester prodrug tenofovir disby M41L, L210W and T215Y produced a significant in-
crease in the amount of rescued and fully extended primers.
These effects were more pronounced for primers termi-
nated with thymidine analogues than for those blocked
with tenofovir, but differences were significant in all cases.hibitors
IC50 (nM)
Tenofovir a Emtricitabine
± 90.5 6.7 ± 2.2 144.3 ± 69.9
± 24.8 (0.5) 12.1 ± 5.3 (1.8) 104.2 ± 81.5 (0.7)
± 75.5 (0.8) 11.0 ± 4.6 (1.6) 226.9 ± 113.2 (1.6)
± 84.5 (1.0) 18.1 ± 4.4 (2.7) 294.7 ± 93.7 (2.0)
each one performed six times. The fold increase in IC50 relative to the wild-
theses.
oproxil fumarate.
Figure 3 Rescue DNA polymerization initiated from AZTMP-, d4TMP-, and tenofovir-terminated primers annealed to a DNA template.
Reactions were carried out with D38/25PGA or D38T/25PGA complexes (sequences given above). The 25-nucleotide primer (lane P) is first
blocked with the nucleotide analogue (lane B). The excision of the inhibitor, followed by extension of the primer is achieved after addition of a
mixture containing 3.2 mM ATP and the four dNTPs. A fully extended 38-nucleotide product is formed. The gel on the right shows a
representative time course experiment of a primer rescue reaction. Lanes 1 to 9 correspond to aliquots removed 2, 4, 6, 8, 10, 12, 15, 20, and
30 minutes after the addition of 3.2 mM ATP. Graphs of time course experiments of primer rescue reactions initiated from inhibitor-terminated
primers are given below. All dNTPs in the assays were supplied at 100 μM, except for dATP or dTTP (depending on the reaction) whose
concentration was 1 μM. Template-primer and active RT concentrations in these assays were 30 and 24 nM, respectively. The values
(averaged± standard deviations [error bars]) were obtained from three independent experiments.
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mediated rescuing ability of the WT RT.
The differences found using DNA/DNA complexes were
not observed with RNA/DNA template-primers (Figure 4).
Although mutant RTs M41L/L210W/T215Y and M41L/
L210W/T215Y/R284K showed remarkable ATP-dependent
phosphorolytic activity, the presence of R284K had a
minimal impact on rescue DNA polymerization initiated
from NRTI-terminated primers. RNase H activity assayscarried out with the RNA/DNA template-primer used in
ATP-mediated rescue experiments demonstrated that the
M41L/L210W/T215Y/R284K RT had increased endonu-
cleolytic activity in comparison with M41L/L210W/
T215Y RT (Figure 5).
The reduced stability of the RNA template in reactions
catalyzed by M41L/L210W/T215Y/R284K RT is consist-
ent with a reduction in the elongation efficiency of
unblocked DNA primers in rescue assays. The mutant
Figure 4 Rescue DNA polymerization initiated from AZTMP-, d4TMP-, and tenofovir-terminated primers annealed to an RNA template.
Time course experiments of excision reactions were carried out in the presence of 3.2 mM ATP. The nucleotide sequences of template-primers
used are given above their corresponding graphs. All dNTPs in the assays were supplied at 200 μM, except for dATP or dTTP (depending on the
reaction) whose concentration was 2 μM. Template-primer and active RT concentrations in these assays were 30 and 24 nM, respectively. The
values (averages standard deviations [error bars]) were obtained from three independent experiments.
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http://www.retrovirology.com/content/9/1/68M41L/L210W/T215Y/R284K RT also showed increased
RNase H activity in comparison with the WT enzyme,
as demonstrated in assays carried out with RNA/DNA
duplexes 38Trna/25PGA and 31Trna/21P (Figure 5). For
example, in assays carried out with 31Trna/21P, the
amount of RNA substrate remaining after 3 minutes of
incubation was <8% for the M41L/L210W/T215Y/
R284K mutant RT, and 35% for WT and M41L/L210W/
T215Y RTs. The catalytic rate constants for RNA tem-
plate cleavage obtained with the M41L/L210W/T215Y/
R284K RT were around 2.5-3 times higher than those
obtained with M41L/L210W/T215Y and WT RTs. An
increased frequency of RNase H secondary cleavageswas also observed with 38Trna/25PGA in reactions cata-
lyzed by the M41L/L210W/T215Y/R284K RT. However,
catalytic rates for these secondary cleavages could not be
determined accurately.
Rescue DNA polymerization assays involve the excision
of the NRTI and the subsequent extension of the
unblocked primer. Excision rates for mutant and WT RTs
were obtained under single-turnover conditions with pri-
mers blocked with thymidine analogues, and annealed to a
DNA template (Figure 6). TAM-containing RTs showed
similar excision rates for AZTMP- and d4TMP-terminated
primers, and ranged from 0.036 to 0.047 min-1. The pres-
ence of R284K did not affect ATP-mediated excision of any
Figure 5 RNase H activity of wild-type and mutants RTs M41L/L210W/T215Y and M41L/L210W/T215Y/R284K. [32P]RNA/DNA substrates
(50 nM) were cleaved at 37°C in the presence of the corresponding RT at 50 nM concentration. Template-primer sequences are shown below.
Arrows in the template sequences indicate the cleavage sites. For D38Trna/25PGA, the time points were taken after incubating the samples for
20 s, 40 s, and 1, 2 and 4 minutes. Catalytic rate constants for the cleavage of D38Trna were 0.34 ± 0.15 min-1, 0.39 ± 0.18 min-1 and
1.16 ± 0.54 min-1 for WT, and mutant RTs M41L/L210W/T215Y and M41L/L210W/T215Y/R284K, respectively. For 31Trna/21P, the time points were
drawn after 20 s, 40 s, and 1, 2, 3 and 4 minutes. The catalytic rate constants with this substrate were 0.33 ± 0.05 min-1 for WT RT, and
0.35 ± 0.03 min-1 and 0.87 ± 0.12 min-1 for mutants M41L/L210W/T215Y and M41L/L210W/T215Y/R284K, respectively. Kinetic data were averages of
three independent experiments.
Betancor et al. Retrovirology 2012, 9:68 Page 8 of 17
http://www.retrovirology.com/content/9/1/68thymidine analogue. On the other hand, as expected, WT
and mutant R284K RTs showed much lower excision rates
(<0.0034 min-1).
R284K increases the DNA polymerization rate when
combined with M41L, L210W and T215Y
The results described above suggested that rescue effi-
ciency differences between M41L/L210W/T215Y and
M41L/L210W/T215Y/R284K RTs could originate from
an altered DNA binding affinity. However, the equili-
brium dissociation constants (Kd) for WT and mutant RTs
and DNA/DNA template-primers showed that differences
between enzymes were not significant (Additional file 1:
Table S3). M41L/L210W/T215Y/R284K RT showed a
slightly higher processivity on heteropolymeric DNAsubstrates in comparison with the M41L/L210W/T215Y
RT (Additional file 1: Figure S2). However, the dissociation
rate constants (koff ) for DNA/DNA template-primers were
similar for both enzymes (i.e. 0.215±0.030 s-1 for M41L/
L210W/T215Y RT and 0.201±0.033 s-1 for M41L/L210W/
T215Y/R284K RT).
Interestingly, M41L/L210W/T215Y/R284K RT showed
increased elongation rates compared with the M41L/
L210W/T215Y RT in assays carried out with unblocked
primers (Additional file 1: Figure S1). These differences
were observed at different concentrations of DNA/DNA
template-primer and in the presence of relatively high con-
centrations of dNTP. Additional experiments carried out
with RTs lacking ATP-dependent excision activity (i.e. WT
and R284K RTs) also showed that the 284 mutation
Figure 6 Kinetics of the ATP-dependent excision of AZTMP and d4TMP from DNA/DNA template-primers. Time course experiments for the
excision reaction of AZTMP- and d4TMP-terminated primers (26-mers) annealed to their corresponding 38-nucleotide DNA templates (30 nM) were
determined in the presence of 3.2 mM ATP. The excision reaction was catalyzed by WT and mutant RTs (210 nM). The calculated kobs values for the AZTMP
excision reaction were 2.82 x 10-3 ± 1.48 x10-4 min-1 for WT RT, 2.42 x 10-3± 1.22 x 10-4 min-1 for mutant R284K RT, 4.69 x 10-2 ±1.69 x 10-3 min-1 for M41L/
L210W/T215Y RT, and 3.64 x10-2 ±3.08 x 10-3 min-1 for M41L/L210W/T215Y/R284K RT. For the excision of d4TMP, the kobs values for WT and mutants
R284K, M41L/L210W/T215Y, and M41L/L210W/T215Y/R284K were 3.37 x 10-3± 1.93 x 10-4 min-1, 2.62 x 10-3 ± 1.42 x 10-4 min-1, 3.72 x 10-2 ±1.58 x 10-3
min-1, and 3.70 x 10-2 ±2.29 x 10-3 min-1, respectively.
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trations of template-primer were not limiting (Additional
file 1: Figure S1).
Steady-state kinetic parameters for dTTP and
dATP incorporation showed that M41L/L210W/
T215Y/R284K RT had an increased catalytic rate of
nucleotide incorporation (kcat), in comparison with
mutant M41L/L210W/T215Y and the WT enzyme
(Table 3). In the case of dATP incorporation, the
catalytic efficiency (kcat/Km) of M41L/L210W/T215Y/
R284K RT was also 2.6 times higher than the cata-
lytic efficiency of the mutant M41L/L210W/T215Y.
Taken together, those data suggest that R284K
improves the rescue efficiency of M41L/L210W/
T215Y RT by promoting dNTP incorporation, par-
ticularly in the presence of relatively high concentra-
tions of nucleotide. On the other hand, R284K
appears to have a minimal impact on AZTTP and
tenofovir-DP binding, since the inhibition constants
(Ki) obtained with WT and mutant RTs under our
assay conditions were similar and around 2 to 3 μM
(Table 3).
It should be noted that although steady-state rates (kcat)
are dominated by the slowest step of the polymerization re-
action (i.e. dissociation of the RT-DNA complex) [41], the
observed kcat differences between M41L/L210W/T215Y
and M41L/L210W/T215Y/R284K RTs are expected to be
relevant because both enzymes have similar koff values. Fur-
ther support of this proposal was obtained from single-
nucleotide incorporation assays carried out under pre-
steady-state conditions, with template-primer D38/25PGA
and at a high dTTP concentration (i.e. 80 μM). In theseexperiments, M41L/L210W/T215Y and M41L/L210W/
T215Y/R284K RTs showed nucleotide incorporation rates
(kobs) of 21.5± 4.4 s
-1 and 38.8±9.4 s-1, respectively. These
results were consistent with an increase in the
polymerization rate mediated by R284K when introduced
in the context of TAM1 mutations.
Discussion
Previous reports showed that the presence of three
or more TAMs (particularly, M41L, T215Y and/or
L210W) compromised the efficacy of tenofovir [42-
44]. These mutations arise after extensive or subopti-
mal treatment with nucleoside analogues, particularly
with AZT or d4T. In agreement with those findings,
our cross-sectional study involving previously treated
patients reveals that the presence of TAMs and
M184V contributes to failure of salvage therapies
containing the combination of tenofovir and emtrici-
tabine, while K65R is relatively rare in those
patients. These results were also consistent with the
low prevalence of K65R in the presence of TAMs, in
patients receiving tenofovir-containing combination
therapies [43,45,46]. K65R exerts an antagonistic ef-
fect on TAMs, by decreasing the ATP-mediated
phosphorolytic activity that facilitates removal of
NRTIs (i.e. thymidine analogues and tenofovir,
among others) from blocked DNA primers [47];
(reviewed in ref. [4]).
Several NNRTI resistance mutations were found to be
more prevalent in the group of patients failing therapy.
In some cases, the presence of these mutations can be
attributed to selection with efavirenz (e.g. K103N), since
Table 3 Steady-state kinetic parameters of nucleotide incorporation catalyzed by wild-type and mutant RTs, and
inhibition constants for AZTTP and tenofovir-DP
RTs Nucleotide kcat (min
-1) Km (nM) kcat/Km (μM
-1 min-1) Ki (AZTTP) (μM) Ki (Tenofovir-DP) (μM)
WT dTTP 3.14 ± 0.55 108.3 ± 12.9 30.9 ± 4.7 2.10 ± 0.38
dATP 3.87 ± 0.99 25.8 ± 6.7 172.0 ± 27.7 3.59 ± 0.26
M41L/L210W/T215Y dTTP 3.53 ± 0.09 117.4 ± 21.9 30.8 ± 6.0 2.18 ± 0.17
dATP 5.70 ± 0.87 32.1 ± 9.6 243.9 ± 51.1 2.63 ± 0.64
M41L/L210W/T215Y/R284K dTTP 5.66 ± 0.23 184.5 ± 6.1 30.7 ± 2.3 2.32 ± 0.74
dATP 10.09 ± 1.47 15.9 ± 2.5 639.6 ± 101.2 2.54 ± 0.55
D38/25PGA and D38T/25PGA were used as substrates for dTTP and dATP incorporation, respectively. Reported values are the averages ± standard deviations,
obtained from at least three independent experiments.
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emtricitabine in 20.2% of the non-responding indivi-
duals. Otherwise, NNRTI resistance mutations may have
arisen from previous treatments with NNRTIs. The pres-
ervation of NNRTI mutations in the viral genome of
treated patients can be attributed to their small effect on
viral fitness, as demonstrated for V108I, Y181C and
G190A [48-51]. Our bivariate analysis also showed that
accessory mutations at positions 35, 39, 162, 174, 179,
208, 223, 228, 284, 292, 297 and 333 could be related to
therapy failure. Among them, T39A, V179I, H208Y,
K223E, L228H/R, R284K and V292I have been previ-
ously identified as secondary mutations associated with
the accumulation of TAMs and with resistance to nu-
cleoside analogues [21,22,35,37,52,53]. On the other
hand, L74V, V179I, K223E and L228H/R were previously
identified as modulators of NNRTI resistance in a large
study carried out in central Italy [23].
Our analysis clearly shows a separate clustering of
TAMs in two different groups that coincides with major
selection pathways, previously identified in patients trea-
ted with thymidine analogues (i.e. TAM1 and TAM2)
[16-18]. Thus, TAM1 includes the amino acid substitu-
tions M41L, L210W and T215Y, while TAM2 contains
mutations D67N, K70R, K219E/Q and sometimes
T215F. In our data set, the TAM1 pathway includes all
three mutations that show high phi values in the correl-
ation analysis. V118I, V179I, M184V and R284K appear
to be associated with the TAM1 pathway. V118I and
M184V are mutations selected under therapy with lami-
vudine (reviewed in refs. [1,4]), while V179I has been
associated with resistance to NNRTIs [54].
Interestingly, the prevalence of R284K seems to in-
crease with the exposure to nucleoside RT inhibitors. In
a study involving more than 2,000 patients treated in
hospitals in the U.K., Cane et al. [22] showed that the
prevalence of R284K increased with the number of
TAMs found in the viral genotype. Only one percent of
the isolates lacking TAMs were found to contain the
mutation. However, the prevalence of R284K increased
up to 4.1%, 6.5% and 9.3% in isolates having 2, 3 or 4TAMs, respectively. Further evidence of this association
was reported by a study of the Swiss Cohort that showed
that the frequency of R284K increased from 1.1% in
naïve individuals to 5.1% in patients treated with thymi-
dine analogues [38]. Interestingly, that analysis also
showed that in those individuals exposed to thymidine
analogues and didanosine, the frequency of R284K was
6.0%, while the frequencies of M41L, L210W, T215Y and
M184V were 48.3%, 36.8%, 57.7% and 1.0%, respectively.
These data together with the strong correlation of
R284K and T215Y in our database suggest that the
emergence of R284K is not related to the selection of
the emtricitabine resistance mutation M184V.
Our results show that R284K has no effect on the viral
susceptibility to thymidine analogues and tenofovir of
isolates containing the TAM1 complex (i.e. M41L/L210W/
T215Y). However, it confers a fitness advantage when the
virus is grown in PBMCs in the presence of drug. Arg284 is
located in the thumb subdomain close to the template
strand and could influence ATP-dependent excision
reaction in a similar way as that reported for other amino
acid substitutions in the HIV-1 RT thumb subdomain
(i.e. P272A/R277K/T286A) [36]. When combined, those
three polymorphisms had a negative effect on the efficiency
of rescue reactions carried out with blocked primers com-
plexed with RNA, and these effects were due to the lower
affinity of the mutant RT for RNA/DNA complexes.
Our biochemical studies showed that in the context of
M41L/L210W/T215Y, the substitution of Lys for Arg284
has no effect on ATP-dependent excision. However,
R284K increases the efficiency of the rescue reaction
and facilitates the elongation of the unblocked primers.
This effect cannot be attributed to an influence on nu-
cleic acid binding or processivity but to the higher cata-
lytic efficiency of the M41L/L210W/T215Y/R284K RT
in comparison with the M41L/L210W/T215Y enzyme.
In combination with TAM1 mutations, R284K produced
60-77% increase in the catalytic rate (kcat) for nucleotide
incorporation. This effect was also consistent with the
higher efficiencies of primer extension observed with the
M41L/L210W/T215Y/R284K RT, using different
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in the catalytic parameters, nucleotide discrimination
seems to play a minor role in the effects of R284K, since
AZTTP and tenofovir-DP inhibition constants (Ki) were
similar for both enzymes. Taken together, these results
could explain why R284K confers a small fitness advan-
tage in the presence of nucleoside analogues, as shown
in the viral replication assays.
Interestingly, the differences in rescue efficiencies be-
tween M41L/L210W/T215Y/R284K and M41L/L210W/
T215Y RTs were found with DNA/DNA template-pri-
mers, but not with RNA/DNA complexes. RNase H
assays carried out with both mutants and the wild-type
RT revealed the higher endonucleolytic activity of
M41L/L210W/T215Y/R284K RT in comparison with
WT and mutant M41L/L210W/T215Y RTs. Therefore,
the minor differences in rescue efficiencies observed
with AZTMP-, d4TMP- or tenofovir-terminated primers
complexed with RNA could be explained by the poor
stability of the template in rescue assays carried out with
the M41L/L210W/T215Y/R284K mutant. It is also pos-
sible that the emergence of R284K in RTs having TAM1
mutations could have a negative impact on the stability of
the viral RNA during reverse transcription, thereby explain-
ing its small but significant reduction in viral fitness in the
absence of inhibitors. Nevertheless, other undetermined
factors may also contribute to this effect. For example, the
potential effects of thumb subdomain mutations on the sta-
bility of the p66/p51 heterodimer [55,56].
The mechanism by which R284K confers a selective
advantage in the context of TAM1 mutations is different
from others previously described for mutations in the
thumb-connection subdomains and in the RNase H do-
main. Thus, mutations such as N348I, A360V and Q509L
increased chain-terminated primer rescue with RNA/DNA
complexes, but not with DNA/DNA template-primers
[29,30,32-34,57,58]. In combination with TAMs, N348I and
A360V decreased the efficiency of RNase H cleavage and
increased excision of AZT in the presence of ATP [34].
Other mutations, such as the complex P272A/R277K/
T286A and G333D had a minor effect on RNase H activity,
but increased chain-terminated primer rescue with both
RNA/DNA and DNA/DNA template-primers [36,59].
It has been suggested that secondary mutations such
as E40F and K43E [25] or L214F [26] that associate
with amino acid substitutions of the TAM1 resist-
ance pathway could increase viral fitness by influen-
cing the catalytic efficiency of the RT. However, the
suggested effects were not supported by biochemical
evidence. In our study we provide an example of a
mutation that improves viral fitness in the presence
of antiretroviral drugs by increasing its RT DNA
polymerase activity, while affecting the RNase H
cleavage efficiency.Conclusions
We have shown evidence of the association of TAM1
mutations (i.e. M41L/L210W/T215Y) with R284K in
previously-treated patients failing salvage therapy with
tenofovir/emtricitabine. Virological studies reveal that
the combination of R284K with TAM1 mutations con-
fers a fitness advantage in the presence of nucleoside
analogues (i.e. AZT and tenofovir), although it has min-
imal impact on phenotypic drug resistance. Biochemical
studies with WT and mutant HIV-1 RTs showed that the
impact of R284K on nucleotide discrimination or ATP-
mediated excision of chain-terminated primers was not sig-
nificant. However, in the presence of the M41L/L210W/
T215Y complex, R284K increases the catalytic rate of nu-
cleotide incorporation and the RNase H activity of the RT,
and these effects promote chain-terminated primer rescue
on DNA/DNA template-primers, but not on RNA/DNA
complexes. Our study unveils a novel mechanism by which
secondary mutations are selected in the context of drug-
resistance mutations and provide further evidence for the
effects of mutations outside the RT DNA polymerase re-
gion subjected to genotypic analysis during the antiretro-
viral treatment.Methods
HIV-1 sequences and antiretroviral treatments
The Spanish AIDS Research Network Drug Resistance
Database is an anonymous clinical database that con-
tains viral genotypes (protease- and RT-coding regions)
derived from 2104 HIV-1-infected patients, treated in 12
Spanish clinics and collected since October 1999 [60].
RT mutation frequencies observed in isolates from patients
failing treatment with tenofovir and emtricitabine (without
additional NRTIs) (104 genotypes) were compared with
those obtained from the naïve population (118 genotypes).
All of the sequences used in the comparison were obtained
between December 2004 and April 2008, and were classi-
fied as of group M – subtype B (GenBank accession num-
bers JX271276 to JX271491). The therapy failure group
included genotypes from patients that had been treated
with the drug combination and showed a viral load of
>1000 copies/ml. All of the patients failing tenofovir/emtri-
citabine had been previously treated with other RT inhibi-
tors (with or without protease inhibitors).Statistical analysis of genotypic data
The frequencies of specific amino acid substitutions in
the first 334 residues of the HIV-1 RT in naïve patients
or in individuals failing treatment with RT inhibitors
was compared using contingency tables and Pearson’s χ2
tests (or Fisher’s exact tests where appropriate). The
Benjamini-Hochberg method was used to identify results
that were statistically significant in the presence of
Betancor et al. Retrovirology 2012, 9:68 Page 12 of 17
http://www.retrovirology.com/content/9/1/68multiple-hypothesis testing [35,61]. A false discovery rate
of 0.05 was used to determine statistical significance.
Mutation covariation was analyzed by calculating the
binomial (phi) correlation coefficient for the simultan-
eous presence of mutations at two positions in the same
isolate. Statistically significant correlations were those
with P ≤ 0.05 using a Bonferroni correction for the num-
ber of possible pair-wise combinations [61,62]. The rela-
tionship among amino acid substitutions found in drug-
resistant isolates was further investigated by principal
axis factoring [63]. The matrix of binomial correlation
coefficients was used as a measure of similarity between
mutations. The factorisability of the correlation matrix
for exploratory factor analysis was judged by Kaiser-
Meyer-Olkin criterion on the basis of the measure of
sampling adequacy. A Bartlett test of sphericity was ap-
plied to test whether correlations differ significantly
from zero, and the number of relevant factors was deter-
mined by reading a scree plot. After extraction, the
resulting factors were orthogonally rotated using the
Varimax procedure. Pattern coefficient cut-offs for the
association of mutations were set at 0.6 for those show-
ing a strong relationship, while values between 0.3 and
0.6 were taken as evidence of moderate covariation. Data
analyses were performed with the SPSS software package
(SPSS Inc, Chicago, Illinois, USA).
Mutagenesis and recombinant HIV-1
Site-directed mutagenesis was carried out with the
Quik-Change Site-Directed Mutagenesis kit (Stratagene)
by following the manufacturer’s instructions, and using
plasmids p66RTB [64] or p66RTB(LY) [36] as templates.
The plasmid p66RTB contains the nucleotide sequence
encoding for the 66-kDa subunit of HIV-1BH10 RT, and
p66RTB(LY) encodes a p66 derivative with thymidine
analogue resistance mutations M41L and T215Y. Muta-
genic primers 5´-GCTGAGACAACATCTGTGGAGGT
GGGGACTTACC-3´ and 5´-GGTAAGTCCCCACCT
CCACAGATGTTGTCTCAGC-3´ were used to intro-
duce L210W in plasmid p66RTB(LY). The mutation
R284K was added with primers 5´-GTAAACTCC
TTAAAGGAACCAAAGCACTAAC-3´ and 5´- GTTA
GTGCTTTGGTTCCTTTAAGGAGTTTAC-3´. All intro-
duced mutations were confirmed by DNA sequencing. Re-
combinant HIV-1 was obtained as previously described
[65]. The full-length RT coding sequence DNA was ampli-
fied with primers IN5 (5′-AATTTTCCCATTAGTCC
TATTGAAACTGTACCA-3′) and IN3 (5′-TCTATTC
CATCYAAAAATAGTACTTTCCTGATTCC-3′), and the
PCR products cotransfected in MT-4 cells with an RT-
deleted HXB2-D clone, previously linearized with BstEII
[66]. MT-4 cells were used to propagate the recombinant
virus [36]. The nucleotide sequence of the RT-coding re-
gion was fully determined in order to check for reversionsor undesired mutations. MT-4 cells and the deleted HXB2-
D clone were obtained from the AIDS Reagent Program
(Medical Research Council).
HIV drug susceptibility, replication capacity and growth
competition assays
Susceptibility to AZT, d4T and tenofovir was determined
in MT-4 cells as previously described [36], using a multi-
plicity of infection of 0.003. Viable cells at different drug
concentrations were quantified with a tetrazolium-based
colorimetric method [67]. Replication kinetics of wild-
type and mutant viruses were assayed by infecting per-
ipheral blood mononuclear cells (PBMCs) (mixed from
two healthy donors), previously stimulated with phyto-
hemagglutinin and interleukin 2 [26]. In these assays,
viral replication rates were obtained from the amounts
of HIV-1 p24Gag antigen produced during the exponen-
tial phase of viral growth, as described previously [26].
Growth competition assays in MT-4 cells were carried out
as previously described [26], in the absence and in the pres-
ence of tenofovir disoproxil fumarate at concentrations ran-
ging from 5 to 80 nM. A multiplicity of infection of 0.001
was used and competing viruses were mixed at a 50:50
ratio. RT inhibitors were obtained from the NIH AIDS Re-
search and Reference Reagent Program.
RT purification
RTs were expressed in E. coli XL1 Blue and purified as p66/
p51 heterodimers by ionic exchange, followed by immobi-
lized metal affinity chromatography on Ni2+-nitriloacetic
acid-agarose [64,68]. The p66 subunit was obtained with a
His6 tag at its C-terminal end to facilitate its purification by
metal affinity chromatography. Purity of the enzymes was
assessed by SDS-polyacrylamide gel electrophoresis and RT
concentrations were determined by active site titration as
described [69,70].
Nucleotides, templates and primers
Stock solutions (100 mM) of dNTPs and ATP were
obtained from GE Healthcare. AZTTP, d4TTP and teno-
fovir diphosphate were purchased from TriLink Biotech-
nologies (San Diego, CA), Sierra Bioresearch (Tucson,
AZ), and Moravek Biochemicals (Brea, CA), respectively.
Before use, nucleoside triphosphates were treated with
inorganic pyrophosphatase (Roche) to remove traces of
PPi [12]. Synthetic oligonucleotides 21P, 25PGA, 31Trna,
D38, D38rna, D38T, D38Trna and ProLac110 were
obtained from Life Technologies. M13mp2 single-
stranded DNA template was purified as described [71].
Primers 25PGA and ProLac110 were labeled at their 5´
termini with [γ-32P]ATP (Perkin Elmer) and T4 poly-
nucleotide kinase (Promega) before annealing them to
their corresponding templates.
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RT-catalyzed DNA rescue reactions were carried out
with DNA/DNA and RNA/DNA duplexes, in 50 mM
Hepes pH 7.0 buffer, containing 15 mM NaCl, 15 mM
magnesium acetate, 130 mM potassium acetate, 1 mM
dithiothreitol and 5% (wt/v) polyethylene glycol [20,36].
Briefly, phosphorylated template-primers (75 nM) were
preincubated with the RT (60 nM) for 10 minutes at
37°C. Then, AZTTP, d4TTP or tenofovir-DP were added
to a final concentration of 25 μM and incubated for an-
other 10 minutes in the same conditions. Rescue reactions
were initiated by adding a mixture of all dNTPs and ATP
at final concentrations of 100 μM each and 3.2 mM, re-
spectively. The final concentration of the next comple-
mentary dNTP (dATP or dTTP under our assay
conditions) was kept at 1 μM in order to minimize its in-
hibitory effect on the rescue reaction, due to the formation
of a “dead-end” complex [39]. Assays with RNA/DNA
complexes such as D38rna/25PGA or D38Trna/25PGA
were carried out as above, but the primer was blocked
with triphosphorylated nucleoside analogues at 50 μM
and dNTP concentrations in the extension reactions were
kept at 200 μM. Rescue and extension reactions were
incubated for 30 minutes at 37°C, with aliquots being
removed at appropriate times. Reactions were stopped by
adding an equal amount of sample loading buffer (10 mM
EDTA in 90% formamide containing 3 mg/ml xylene cya-
nol FF and 3 mg/ml bromophenol blue). Products were
resolved on a 20% polyacrylamide–8 M urea gel, and pri-
mer rescue was quantified by phosphorimaging, using a
BAS1500 scanner (Fuji) and the program Tina version
2.09 (Raytest Isotopenmessgerate GmbH, Staubenhardt,
Germany).
Pre-steady-state kinetics of the ATP-dependent excision
reaction
The primer 25PGA was blocked at its 3´ end with d4TTP
using terminal deoxynucleotidyltransferase (Roche) [12],
and excess nucleotides were eliminated by repeated passage
through a mini Quick Spin column (Roche). The blocked
primer was then labeled with [γ-32P]ATP and T4 poly-
nucleotide kinase and annealed to the DNA template D38,
in order to obtain the template-primer D38/25PGAd4T,
used in the excision reactions. Since AZTTP is not a sub-
strate of terminal deoxynucleotidyltransferase, we had to
use WT HIV-1BH10 RT to block the template-primer D38/
25PGA with AZT. For this purpose, we preincubated the
template-primer D38/[32P]25PGA (4.6 μM) with HIV-
1BH10 RT (4 μM) in 65 μl of 50 mM Hepes pH 7.0 buffer,
containing 15 mM NaCl, 15 mM magnesium acetate,
130 mM potassium acetate, 1 mM dithiothreitol, and 5%
polyethylene glycol for 10 minutes at 37°C. Then, 35 μl of
6 mM AZTTP (diluted in the preincubation buffer) were
added and incubated for another 30 minutes at 37°C toensure that the primer was blocked completely. The RT
was inactivated by heating the mixture for 10 minutes at
90°C. After slowly cooling the sample at room temperature,
it was passaged several times through a mini Quick Spin
column (Roche) to eliminate the free AZTTP. Finally, the
D38/25PGAAZT template-primer was obtained after pre-
cipitation with 98% ethanol. The excision of d4T monopho-
sphate (d4TMP) from D38/25PGAd4T was determined
under single turnover conditions, as previously described
[36]. The same conditions were used to study the excision
of AZTMP from template-primer D38/25PGAAZT.
DNA binding affinity
Dissociation equilibrium constants (Kd) for RTs and DNA
duplexes were obtained with the template-primer D38/
25PGA by following a previously described procedure [36].
Kinetics of nucleotide incorporation and determination of
inhibition constants for AZTTP and tenofovir-DP
Nucleotide incorporation reactions under steady-state
conditions were carried out as previously described [72].
However, in the preincubation buffer, active RT and
template-primers D38/25PGA or D38T/25PGA were
present at concentrations of 7–20 nM and 60 nM, re-
spectively. Elongation rates were determined with dTTP
concentrations ranging from 0.05 to 20 μM or with
dATP concentrations ranging from 12 nM to 10 μM,
using reaction volumes of 20 μl. Catalytic constants kcat
and Km were determined after fitting the elongation data
to the Michaelis–Menten equation as described [73]. In-
hibition constants (Ki) for AZTTP and tenofovir-DP
were determined under the conditions used for obtain-
ing the catalytic constants of dTTP and dATP incorpor-
ation, respectively. In order to distinguish between
dTTP and AZTTP, elongation reactions were carried out
under conditions that allowed the incorporation of two
nucleotides (i.e. T at position +1 and A at position +2).
For this purpose dATP was supplied at 1 μM in all
assays. The competition between tenofovir-DP and
dATP was analyzed with template-primer D38T/25PGA.
Assays were carried out with variable concentrations of
dATP (as indicated above) and 2 μM dTTP to facilitate
further extension of the primer when the inhibitor was
not incorporated at position +1 of the DNA primer.
Data were analyzed by using Lineweaver-Burk plots. Nu-
cleotide incorporation reactions under pre-steady-state
conditions were carried out with template-primer D38/
25PGA, as described [72].
Primer extension
These experiments were carried out after preincubating
the template-primer (D38/25PGA) at concentrations of
3, 10 and 20 nM with the corresponding RT (6 nM) in
25 μl or 100 mM Hepes pH 7.0 buffer, containing
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tassium acetate, 1 mM dithiothreitol, and 5% polyethyl-
ene glycol. After 10 minutes at 37°C, all four dNTPs
were added to a final concentration of 100 μM, in a so-
lution containing 130 mM potassium acetate, 1 mM
dithiothreitol, and 5% polyethylene glycol. Aliquots of
4 μl were removed at appropriate times and quenched
with an equal volume of sample loading buffer, before
analyzing the products by denaturing polyacrylamide gel
electrophoresis and phosphorimaging.
Processivity
The processivity of wild-type and mutant RTs was
assessed with a complex made of M13mp2 single-
stranded DNA as template and ProLac110 (5’- GCGAT
TAAGTTGGGT-3’) as primer, and with the 38/25-mer
D38/25PGA. RTs and template-primer (both at 60 nM
concentration) were preincubated at 37°C for 10 minutes
in 12 μl of 50 mM Tris–HCl pH 8.0 buffer, containing
50 mM KCl. Reactions were initiated by adding 12 μl of
preincubation buffer containing 12 mM MgCl2 and a
mixture of the four dNTPs (at 100 μM each) with or
without 10 mg/ml sodium heparin. Aliquots of 4 μl were
removed after 5, 15, 30 and 45 minutes and quenched
with an equal volume of sample loading buffer. Products
were resolved by denaturing polyacrylamide gel electro-
phoresis and analyzed as described above.
RNase H assays
RNase H activity of mutant and WT RTs was deter-
mined with template-primers 31Trna/21P and D38Trna/
25PGA as previously described [36,74].
Additional file
Additional file 1: Contains Tables S1, S2 and S3 and Figures S1 and
S2. Table S1. Correlated pairs of RT mutations in isolates from patients
failing therapy with tenofovir and emtricitabine. Table S2. Factor analysis
of the 25 correlated amino acid substitutions associated with tenofovir/
emtricitabine therapy failure. Table S3. Dissociation equilibrium constants
for WT and mutant HIV-1 RTs and DNA/DNA template-primers. Figure S1.
Extension of unblocked DNA primer 25PGA by WT and mutant RTs in the
presence of a DNA template. Reactions were carried out with template-
primer concentrations of 1.5, 5 and 10 nM, in the presence of 3 nM RT
and 100 μM of each dNTP. The represented values shown in the plots
below were averages ± standard deviations [error bars], obtained from
three independent experiments. Figure S2. Processivity of wild-type and
mutant RTs. (A) Processivity assays with M13mp2 single-stranded DNA as
template. Elongation reactions were monitored in the presence of
heparin (5 mg/ml) as an enzyme trap. After formation of the binary
complex of RT and template-primer (M13mp2 single-stranded DNA/
ProLac110), reactions were initiated after addition of a mixture of all four
dNTPs (50 μM final concentration), with or without heparin (indicated
above with plus and minus signs, respectively). Lanes 1 to 4 represent
samples taken 5, 15, 30 and 45 minutes after initiating the polymerization
reaction. P stands for primer, and C represents control reactions where
the enzyme was added after the heparin trap. The oligonucleotide
ProLac110 (5’- GCGATTAAGTTGGGT-3’) is complementary to positions
105–119 of the lacZα coding sequence. (B) Processivity assays with M41L/L210W/T215Y and M41L/L210W/T215Y/R284K RTs using the
heteropolymeric template-primer D38/25PGA. Assays were carried out in
the same conditions described above for M13mp2 single-stranded DNA/
ProLac110. (C) Relative amounts of extended primer in reactions carried
out with D38/25PGA in the presence of trap. Asterisks indicate bands
that are significantly more intense in the reactions catalyzed by the
M41L/L210W/T215Y/R284K RT.
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